Document is current
Any future updates will be listed below
-
Authors
Pardanani, A
Lasho, T
Chen, D
Kimlinger, T K
Finke, C
Zblewski, D
Patnaik, M M
Reichard, K K
Rowinsky, E
Hanson, C A
Brooks, C
Tefferi, A
- License Information
-
More Information
Article History
First Online: 2 February 2015
Competing interests
: AP received research funding from Stemline Therapeutics Inc. for the flow cytometry experiments. AP is Principal Investigator for a forthcoming clinical trial of SL-401 for treatment of myeloproliferative neoplasms. SL-401 is a CD123-targeting investigational drug manufactured by Stemline Therapeutics Inc. CB and ER are employees of Stemline Therapeutics Inc.
